MannKind Corporation (MNKD) Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $82 million, a 17% increase year-over-year.

Tyvaso DPI Revenue: $33 million in royalties (up 23%) and $26 million in manufacturing revenue.

Afrezza Revenue: $18.5 million, reflecting a 23% increase year-over-year.

VGo Revenue: $3.8 million, down 19% year-over-year.

GAAP Net Income: $8 million, down from $11.6 million in Q3 2024.

Non-GAAP Net Income: $22.4 million, up from $15.4 million year-over-year, with non-GAAP EPS of $0.07.

Year-to-Date Revenue: $237 million, a 14% increase compared to the same period in 2024.

2Strategic Updates and Business Highlights

Acquisition of scPharmaceuticals: Completed, expected to enhance growth through FUROSCIX and inhaled bumetanide (MNKD-701).

Pipeline Progress: Afrezza supplemental BLA accepted for review with a PDUFA date in Q2 2026; sNDA for FUROSCIX auto-injector submitted with a PDUFA date in Q3 2026.

Tyvaso DPI Performance: Strong growth with an 80-microgram cartridge developed for improved patient convenience.

FUROSCIX Adoption: 27,000 doses dispensed in Q3, a 153% increase year-over-year, with revenue of $19.3 million expected in Q4 following the acquisition.

Sales Force Expansion: Integration of scPharmaceuticals' team into MannKind's structure, with a focus on enhancing market presence.

3Forward Guidance and Outlook

Anticipation of continued revenue growth driven by Afrezza and FUROSCIX, with a focus on pediatric indications for Afrezza.

Expectation of increased share of voice and prescribing rates in the coming quarters, particularly as the pediatric launch approaches.

Guidance for Q4 includes the addition of FUROSCIX sales, which will significantly impact overall revenue.

4Bad News, Challenges, or Points of Concern

Declining Metrics: Afrezza's units per prescription have decreased by about 15% year-over-year as the focus shifts to type 1 diabetes, impacting revenue growth relative to total prescriptions.

Increased Expenses: R&D expenses rose by 9%, and SG&A expenses increased by 22%, driven by investments in Afrezza and the integration of scPharmaceuticals.

Competitive Pressures: New competitors for FUROSCIX have emerged, raising concerns about market share and pricing strategies, particularly in the Medicare segment where out-of-pocket costs remain a barrier.

Debt Obligations: A $36 million convertible debt is due in March 2026, raising concerns about cash flow management and deleveraging priorities.

5Notable Q&A Insights

Integration of scPharmaceuticals: Integration is progressing smoothly with minimal disruption, and the sales force is expected to expand strategically.

Afrezza Growth: Q4 is expected to show strong performance; however, sales may not immediately align with TRx growth due to ongoing prescription trends.

Competitive Landscape: Management is confident in FUROSCIX's differentiation and believes that increased market presence will benefit overall sales despite new entrants.

Pediatric Opportunity for Afrezza: Research indicates potential for significant market share, with estimates suggesting up to $150 million in net revenue at 10% market share. Overall, MannKind is positioned for growth through strategic acquisitions and product development, though it faces challenges related to competition and market dynamics.